Amyloid beta (Aβ) is a peptide implicated in Alzheimer's disease and other forms of dementia. It forms when amyloid precursor protein (APP) is improperly cleaved by enzymes. Accumulating Aβ peptides aggregate into plaques, a hallmark of Alzheimer's pathology. These plaques disrupt cell function, trigger inflammation, and promote neuronal death, contributing to cognitive decline and memory loss. Research aims to understand the mechanisms of Aβ formation and aggregation, seeking therapeutic strategies to prevent or reduce plaque buildup. Despite its central role in Alzheimer’s, the exact relationship between amyloid beta and disease progression remains complex, involving genetic, environmental, and biochemical factors.
Title : Make a difference
Jacqueline Tuppen, Dementia UK, United Kingdom
Title : Imaging brain clearance in Alzheimer’s disease
Jun Hua, Johns Hopkins University , United States
Title : Association between APOE allele prevalence and Alzheimer's disease risk in Southwestern Uganda
Frank Balikoowa, African Research Center for Ageing & Dementia, Uganda
Title : Healthcare professionals in Somaliland had low levels of knowledge and attitudes towards dementia care: A pilot survey
Mohamed Abdilahi Duale, Frantz Fanon University, Somalia
Title : Association between depressive symptoms and cognitive impairment severity in a real-world memory clinic cohort
Yun Ju Hsieh, Taipei City Hospital, Taiwan
Title : Neuromodulation of scalp electroacupuncture in the treatment of autism spectrum disorder
Zhenhuan Liu, Nanhai Maternity and Children Hospital Affiliated to Guangzhou University of Chinese Medicine, China